XMD8-87

ATP competitive inhibitor of TNK2

Structure

Information

  • TNK2
  • ATP competitive inhibitor
  • up to 500 nM

In Vitro Validations

Uniprot ID: Q07912
Target Class: Protein kinase
Target SubClass: TK
Potency: KD, IC50
Potency Value: 15, 35.4 nM
Potency Assay: Ambit binding assay (KD), Invitrogen Kinase assay
PDB ID for probe-target interaction (3D structure): --
Target aliases:
Activated CDC42 kinase 1, ACK1, TNK2, ACK1_HUMAN, ...

In Cell Validations

In Vivo Data

No in Vivo Validations

Off-Target Selectivity Assesments

Potency end-point : KD, IC50 BRK 37 nM, 47 nM
Potency assay (off target): Ambit binding assay, Invitrogen kinase assay
Probe Selectivity in Vitro:

CSF1R (330 nM Kd in Ambit binding assay, 428 nM IC50 in Invitrogen kinase assay); DCAMKL1 (280 nM Kd in Ambit binding assay); DCAMKL2 (690 nM Kd in Ambit binding assay, 3200 nM IC50 in Invitrogen kinase assay); FRK (96 nM Kd in Ambit binding assay, 264 nM IC50 in Invitrogen kinase assay); GAK (270 nM Kd in Ambit binding assay); TNK1 (110 nM Kd in Ambit binding assay)

I have extra information to add

SERP ratings and comments


SERP Ratings

In Cell Rating

SERP Comments:

Although direct live cell target engagement was not determined, the cell-free and phenotypic data support use of this probe as a selective tool in cellular studies at the concentrations proposed. 

(last updated: 10 Nov 2020 )

SERP Ratings

In Cell Rating

SERP Comments:

This probe is based on a well-known scaffold that has yielded inhibitors of various kinases, including the ones listed in the specificity section, and ERK5. The scaffold also has a known bromodomain inhibition activity (DOI: 10.1126/scisignal.aal2473). Any use of this inhibitor should also have controls from different structural classes that inhibit ERK5 (eg BAY-885) and BRDs (eg JQ1)

(last updated: 18 Feb 2021 )

SERP Ratings

In Cell Rating

SERP Comments:

The selectivity of XMD-8-87 is concerning with respect to BRK and FRK. If XMD-8-87 is to be used as a probe for ACK1, care must be exercised to exclude off-targets BRK and FRK. There is no data on non kinase off-targets reported.

(last updated: 19 Apr 2021 )